-
1
-
-
20444433230
-
Bortezomib or high-dose dexamethasone for relapsed multiple myeloma
-
Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med. 2005;352(24):2487-98.
-
(2005)
N Engl J Med
, vol.352
, Issue.24
, pp. 2487-2498
-
-
Richardson, P.G.1
Sonneveld, P.2
Schuster, M.W.3
Irwin, D.4
Stadtmauer, E.A.5
Facon, T.6
-
2
-
-
35148825003
-
Extended follow-up of a phase 3 trial in relapsed multiple myeloma: Final time-toevent results of the APEX trial
-
Richardson PG, Sonneveld P, Schuster M, Irwin D, Stadtmauer E, Facon T, et al. Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-toevent results of the APEX trial. Blood. 2007; 110(10):3557-60.
-
(2007)
Blood
, vol.110
, Issue.10
, pp. 3557-3560
-
-
Richardson, P.G.1
Sonneveld, P.2
Schuster, M.3
Irwin, D.4
Stadtmauer, E.5
Facon, T.6
-
3
-
-
34548539381
-
Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: Combination therapy improves time to progression
-
Orlowski RZ, Nagler A, Sonneveld P, Blade J, Hajek R, Spencer A, et al. Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. J Clin Oncol. 2007;25(25):3892-901.
-
(2007)
J Clin Oncol
, vol.25
, Issue.25
, pp. 3892-3901
-
-
Orlowski, R.Z.1
Nagler, A.2
Sonneveld, P.3
Blade, J.4
Hajek, R.5
Spencer, A.6
-
4
-
-
84868096248
-
Updated survival analysis of a randomrandomized phase III study of subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma
-
Arnulf B, Pylypenko H, Grosicki S, Karamanesht I, Leleu X, van de Velde H, et al. Updated survival analysis of a randomrandomized phase III study of subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma. Haematologica. 2012;97(12):1925-8.
-
(2012)
Haematologica
, vol.97
, Issue.12
, pp. 1925-1928
-
-
Arnulf, B.1
Pylypenko, H.2
Grosicki, S.3
Karamanesht, I.4
Leleu, X.5
Van De Velde, H.6
-
5
-
-
5644250621
-
A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma
-
Jagannath S, Barlogie B, Berenson J, Siegel D, Irwin D, Richardson PG, et al. A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol. 2004;127(2):165-72.
-
(2004)
Br J Haematol
, vol.127
, Issue.2
, pp. 165-172
-
-
Jagannath, S.1
Barlogie, B.2
Berenson, J.3
Siegel, D.4
Irwin, D.5
Richardson, P.G.6
-
6
-
-
33745801771
-
Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and/or refractory multiple myeloma with less than optimal response to bortezomib alone
-
Jagannath S, Richardson PG, Barlogie B, Berenson JR, Singhal S, Irwin D, et al. Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and/or refractory multiple myeloma with less than optimal response to bortezomib alone. Haematologica. 2006; 91(7):929-34.
-
(2006)
Haematologica
, vol.91
, Issue.7
, pp. 929-934
-
-
Jagannath, S.1
Richardson, P.G.2
Barlogie, B.3
Berenson, J.R.4
Singhal, S.5
Irwin, D.6
-
7
-
-
54849413402
-
Updated survival analyses after prolonged follow-up of the phase 2, multicenter CREST study of bortezomib in relapsed or refractory multiple myeloma
-
Jagannath S, Barlogie B, Berenson JR, Siegel DS, Irwin D, Richardson PG, et al. Updated survival analyses after prolonged follow-up of the phase 2, multicenter CREST study of bortezomib in relapsed or refractory multiple myeloma. Br J Haematol. 2008;143(4):537-40.
-
(2008)
Br J Haematol
, vol.143
, Issue.4
, pp. 537-540
-
-
Jagannath, S.1
Barlogie, B.2
Berenson, J.R.3
Siegel, D.S.4
Irwin, D.5
Richardson, P.G.6
-
8
-
-
58149086029
-
High response rate to bortezomib with or without dexamethasone in patients with relapsed or refractory multiple myeloma: Results of a global phase 3b expanded access program
-
Mikhael JR, Belch AR, Prince HM, Lucio MN, Maiolino A, Corso A, et al. High response rate to bortezomib with or without dexamethasone in patients with relapsed or refractory multiple myeloma: results of a global phase 3b expanded access program. Br J Haematol. 2009; 144(2):169-75.
-
(2009)
Br J Haematol
, vol.144
, Issue.2
, pp. 169-175
-
-
Mikhael, J.R.1
Belch, A.R.2
Prince, H.M.3
Lucio, M.N.4
Maiolino, A.5
Corso, A.6
-
9
-
-
79955461011
-
Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: A randomised, phase 3, non-inferiority study
-
Moreau P, Pylypenko H, Grosicki S, Karamanesht I, Leleu X, Grishunina M, et al. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol. 2011;12(5):431-40.
-
(2011)
Lancet Oncol
, vol.12
, Issue.5
, pp. 431-440
-
-
Moreau, P.1
Pylypenko, H.2
Grosicki, S.3
Karamanesht, I.4
Leleu, X.5
Grishunina, M.6
-
10
-
-
0037973279
-
A phase 2 study of bortezomib in relapsed, refractory myeloma
-
Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med. 2003;348(26):2609-17.
-
(2003)
N Engl J Med
, vol.348
, Issue.26
, pp. 2609-2617
-
-
Richardson, P.G.1
Barlogie, B.2
Berenson, J.3
Singhal, S.4
Jagannath, S.5
Irwin, D.6
-
11
-
-
33644844108
-
Extended follow-up of a phase II trial in relapsed, refractory multiple myeloma: Final time-to-event results from the SUMMIT trial
-
Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin DH, et al. Extended follow-up of a phase II trial in relapsed, refractory multiple myeloma: final time-to-event results from the SUMMIT trial. Cancer. 2006;106(6):1316-9.
-
(2006)
Cancer
, vol.106
, Issue.6
, pp. 1316-1319
-
-
Richardson, P.G.1
Barlogie, B.2
Berenson, J.3
Singhal, S.4
Jagannath, S.5
Irwin, D.H.6
-
12
-
-
84885367423
-
Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
-
Moreau P, San Miguel JF, Ludwig H, Schouten H, Mohty M, Dimopoulos M, et al. Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24(Suppl 6):vi133-7.
-
(2013)
Ann Oncol
, vol.24
, pp. 133-137
-
-
Moreau, P.1
San Miguel, J.F.2
Ludwig, H.3
Schouten, H.4
Mohty, M.5
Dimopoulos, M.6
-
13
-
-
84874630363
-
Multiple myeloma, version 1.2013
-
Anderson KC, Alsina M, Bensinger W, Biermann JS, Cohen AD, Devine S, et al. Multiple myeloma, version 1.2013. J Natl Compr Canc Netw. 2013;11(1):11-7.
-
(2013)
J Natl Compr Canc Netw
, vol.11
, Issue.1
, pp. 11-17
-
-
Anderson, K.C.1
Alsina, M.2
Bensinger, W.3
Biermann, J.S.4
Cohen, A.D.5
Devine, S.6
-
14
-
-
84881016175
-
Phase II study of bortezomib-dexamethasone alone or with added cyclophosphamide or lenalidomide for sub-optimal response as second-line treatment for patients with multiple myeloma
-
Dimopoulos MA, Beksac M, Benboubker L, Roddie H, Allietta N, Broer E, et al. Phase II study of bortezomib-dexamethasone alone or with added cyclophosphamide or lenalidomide for sub-optimal response as second-line treatment for patients with multiple myeloma. Haematologica. 2013;98(8):1264-72.
-
(2013)
Haematologica
, vol.98
, Issue.8
, pp. 1264-1272
-
-
Dimopoulos, M.A.1
Beksac, M.2
Benboubker, L.3
Roddie, H.4
Allietta, N.5
Broer, E.6
-
15
-
-
84920126185
-
Bortezomib and dexamethasone from cycle 1 as treatment and maintenance for multiple myeloma relapse (the BoMeR trial) significantly improves response and time to progression: A matched analysis of BoMeR vs APEX
-
Abstract
-
Harrison S, Quach H, Link E, Feng H, Dean J, Copeman M, et al. Bortezomib and dexamethasone from cycle 1 as treatment and maintenance for multiple myeloma relapse (the BoMeR trial) significantly improves response and time to progression: a matched analysis of BoMeR vs APEX. Haematologica. 2011;96(S1): Abstract P-236.
-
(2011)
Haematologica
, vol.96
, Issue.S1
, pp. 236
-
-
Harrison, S.1
Quach, H.2
Link, E.3
Feng, H.4
Dean, J.5
Copeman, M.6
-
16
-
-
84988241358
-
International uniform response criteria for multiple myeloma
-
Durie BG, Harousseau JL, Miguel JS, Blade J, Barlogie B, Anderson K, et al. International uniform response criteria for multiple myeloma. Leukemia. 2006;20(9): 1467-73.
-
(2006)
Leukemia
, vol.20
, Issue.9
, pp. 1467-1473
-
-
Durie, B.G.1
Harousseau, J.L.2
Miguel, J.S.3
Blade, J.4
Barlogie, B.5
Anderson, K.6
-
17
-
-
18244428600
-
Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant
-
Blade J, Samson D, Reece D, Apperley J, Bjorkstrand B, Gahrton G, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol. 1998;102(5): 1115-23.
-
(1998)
Br J Haematol
, vol.102
, Issue.5
, pp. 1115-1123
-
-
Blade, J.1
Samson, D.2
Reece, D.3
Apperley, J.4
Bjorkstrand, B.5
Gahrton, G.6
-
18
-
-
33846842327
-
A comparison of the ability of different propensity score models to balance measured variables between treated and untreated subjects: A Monte Carlo study
-
Austin PC, Grootendorst P, Anderson GM. A comparison of the ability of different propensity score models to balance measured variables between treated and untreated subjects: a Monte Carlo study. Stat Med. 2007;26(4):734-53.
-
(2007)
Stat Med
, vol.26
, Issue.4
, pp. 734-753
-
-
Austin, P.C.1
Grootendorst, P.2
Anderson, G.M.3
-
19
-
-
44649173785
-
A critical appraisal of propensity- score matching in the medical literature between 1996 and 2003
-
Austin PC. A critical appraisal of propensity- score matching in the medical literature between 1996 and 2003. Stat Med. 2008; 27(12):2037-49.
-
(2008)
Stat Med
, vol.27
, Issue.12
, pp. 2037-2049
-
-
Austin, P.C.1
-
20
-
-
79951791644
-
A tutorial and case study in propensity score analysis: An application to estimating the effect of in-hospital smoking cessation counseling on mortality
-
Austin PC. A tutorial and case study in propensity score analysis: an application to estimating the effect of in-hospital smoking cessation counseling on mortality. Multivariate Behav Res. 2011;46(1):119-51.
-
(2011)
Multivariate Behav Res
, vol.46
, Issue.1
, pp. 119-151
-
-
Austin, P.C.1
-
21
-
-
79955936633
-
Prognostic factor analyses of myeloma survival with intergroup trial S9321 (INT 0141): Examining whether different variables govern different time segments of survival
-
Barlogie B, Bolejack V, Schell M, Crowley J. Prognostic factor analyses of myeloma survival with intergroup trial S9321 (INT 0141): examining whether different variables govern different time segments of survival. Ann Hematol. 2011;90(4):423-8.
-
(2011)
Ann Hematol
, vol.90
, Issue.4
, pp. 423-428
-
-
Barlogie, B.1
Bolejack, V.2
Schell, M.3
Crowley, J.4
-
22
-
-
84878468191
-
Age and organ damage correlate with poor survival in myeloma patients: Meta-analysis of 1435 individual patient data from 4 randomized trials
-
Bringhen S, Mateos MV, Zweegman S, Larocca A, Falcone AP, Oriol A, et al. Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials. Haematologica. 2013;98(6): 980-7.
-
(2013)
Haematologica
, vol.98
, Issue.6
, pp. 980-987
-
-
Bringhen, S.1
Mateos, M.V.2
Zweegman, S.3
Larocca, A.4
Falcone, A.P.5
Oriol, A.6
-
23
-
-
84873904996
-
Extramedullary plasmacytoma in the presence of multiple myeloma: Clinical correlates and prognostic relevance
-
Chen HF, Wu TQ, Li ZY, Shen HS, Tang JQ, Fu WJ, et al. Extramedullary plasmacytoma in the presence of multiple myeloma: clinical correlates and prognostic relevance. Onco Targets Ther. 2012;5329-34.
-
(2012)
Onco Targets Ther
, pp. 5329-5334
-
-
Chen, H.F.1
Wu, T.Q.2
Li, Z.Y.3
Shen, H.S.4
Tang, J.Q.5
Fu, W.J.6
-
24
-
-
20644460600
-
International staging system for multiple myeloma
-
Greipp PR, San Miguel JF, Durie BG, Crowley J., Barlogie B, Blade J, et al. International staging system for multiple myeloma. J Clin Oncol. 2005;23(15): 3412-20.
-
(2005)
J Clin Oncol
, vol.23
, Issue.15
, pp. 3412-3420
-
-
Greipp, P.R.1
San Miguel, J.F.2
Durie, B.G.3
Crowley, J.4
Barlogie, B.5
Blade, J.6
-
25
-
-
19944428373
-
An evaluation of factors predicting long-term response to thalidomide in 234 patients with relapsed or resistant multiple myeloma
-
Hus I, Dmoszynska A, Manko J, Hus M, Jawniak D, Soroka-Wojtaszko M, et al. An evaluation of factors predicting long-term response to thalidomide in 234 patients with relapsed or resistant multiple myeloma. Br J Cancer. 2004;91(11):1873-9.
-
(2004)
Br J Cancer
, vol.91
, Issue.11
, pp. 1873-1879
-
-
Hus, I.1
Dmoszynska, A.2
Manko, J.3
Hus, M.4
Jawniak, D.5
Soroka-Wojtaszko, M.6
-
26
-
-
0030053770
-
Prognostic factors in multiple myeloma: Selection using Cox's proportional hazard model
-
Pasqualetti P, Collacciani A, Maccarone C, Casale R. Prognostic factors in multiple myeloma: selection using Cox's proportional hazard model. Biomed Pharmacother. 1996;50(1):29-35.
-
(1996)
Biomed Pharmacother
, vol.50
, Issue.1
, pp. 29-35
-
-
Pasqualetti, P.1
Collacciani, A.2
Maccarone, C.3
Casale, R.4
-
27
-
-
57949103908
-
Staging multiple myeloma patients with active disease using serum levels of beta2m-free HLA class I heavy chain together with IgM or platelet count
-
Perosa F, Minoia C, Favoino E, Prete M, Dammacco F. Staging multiple myeloma patients with active disease using serum levels of beta2m-free HLA class I heavy chain together with IgM or platelet count. Blood Cells Mol Dis. 2009;42(1):71-6.
-
(2009)
Blood Cells Mol Dis
, vol.42
, Issue.1
, pp. 71-76
-
-
Perosa, F.1
Minoia, C.2
Favoino, E.3
Prete, M.4
Dammacco, F.5
-
28
-
-
0035196437
-
Methods for estimation of bone marrow plasma cell involvement in myeloma: Predictive value for response and survival in patients undergoing autologous stem cell transplantation
-
Rajkumar SV, Fonseca R, Dispenzieri A, Lacy MQ, Lust JA, Witzig TE, et al. Methods for estimation of bone marrow plasma cell involvement in myeloma: predictive value for response and survival in patients undergoing autologous stem cell transplantation. Am J Hematol. 2001; 68(4):269-75.
-
(2001)
Am J Hematol
, vol.68
, Issue.4
, pp. 269-275
-
-
Rajkumar, S.V.1
Fonseca, R.2
Dispenzieri, A.3
Lacy, M.Q.4
Lust, J.A.5
Witzig, T.E.6
-
29
-
-
27644476353
-
Clinical factors predictive of outcome with bortezomib in patients with relapsed, refractory multiple myeloma
-
Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, et al. Clinical factors predictive of outcome with bortezomib in patients with relapsed, refractory multiple myeloma. Blood. 2005; 106(9):2977-81.
-
(2005)
Blood
, vol.106
, Issue.9
, pp. 2977-2981
-
-
Richardson, P.G.1
Barlogie, B.2
Berenson, J.3
Singhal, S.4
Jagannath, S.5
Irwin, D.6
-
30
-
-
77951882321
-
Incidence, presenting features and outcome of extramedullary disease in multiple myeloma: A longitudinal study on 1003 consecutive patients
-
Varettoni M, Corso A, Pica G, Mangiacavalli S, Pascutto C, Lazzarino M. Incidence, presenting features and outcome of extramedullary disease in multiple myeloma: a longitudinal study on 1003 consecutive patients. Ann Oncol. 2010;21 (2):325-30.
-
(2010)
Ann Oncol
, vol.21
, Issue.2
, pp. 325-330
-
-
Varettoni, M.1
Corso, A.2
Pica, G.3
Mangiacavalli, S.4
Pascutto, C.5
Lazzarino, M.6
-
31
-
-
14744278225
-
Bortezomib in combination with dexamethasone for relapsed multiple myeloma
-
Kropff MH, Bisping G, Wenning D, Volpert S, Tchinda J, Berdel WE, et al. Bortezomib in combination with dexamethasone for relapsed multiple myeloma. Leuk Res. 2005;29(5):587-90.
-
(2005)
Leuk Res
, vol.29
, Issue.5
, pp. 587-590
-
-
Kropff, M.H.1
Bisping, G.2
Wenning, D.3
Volpert, S.4
Tchinda, J.5
Berdel, W.E.6
-
32
-
-
78549269073
-
Bortezomib plus dexamethasone for relapsed or treatment refractory multiple myeloma: The collaborative study at six institutes in Kyoto and Osaka
-
Kobayashi T, Kuroda J, Shimura K, Akaogi T, Kawata E, Kiyota M, et al. Bortezomib plus dexamethasone for relapsed or treatment refractory multiple myeloma: the collaborative study at six institutes in Kyoto and Osaka. Int J Hematol. 2010;92(4):579-86.
-
(2010)
Int J Hematol
, vol.92
, Issue.4
, pp. 579-586
-
-
Kobayashi, T.1
Kuroda, J.2
Shimura, K.3
Akaogi, T.4
Kawata, E.5
Kiyota, M.6
-
33
-
-
70349971700
-
Bortezomib plus dexamethasone is highly effective in relapsed and refractory myeloma patients but responses are short-lived
-
Corso A, Varettoni M, Mangiacavalli S, Zappasodi P, Pica GM, Algarotti A, et al. Bortezomib plus dexamethasone is highly effective in relapsed and refractory myeloma patients but responses are short-lived. Eur J Haematol. 2009;83(5):449-54.
-
(2009)
Eur J Haematol
, vol.83
, Issue.5
, pp. 449-454
-
-
Corso, A.1
Varettoni, M.2
Mangiacavalli, S.3
Zappasodi, P.4
Pica, G.M.5
Algarotti, A.6
-
34
-
-
84891855990
-
Bortezomib and dexamethasone as salvage therapy in patients with relapsed/refractory multiple myeloma: Analysis of long-term clinical outcomes
-
Pantani L, Zamagni E, Zannetti BA, Pezzi A, Tacchetti P, Brioli A, et al. Bortezomib and dexamethasone as salvage therapy in patients with relapsed/refractory multiple myeloma: analysis of long-term clinical outcomes. Ann Hematol. 2013;93(1):123-8.
-
(2013)
Ann Hematol
, vol.93
, Issue.1
, pp. 123-128
-
-
Pantani, L.1
Zamagni, E.2
Zannetti, B.A.3
Pezzi, A.4
Tacchetti, P.5
Brioli, A.6
-
35
-
-
84920131142
-
Efficacy of bortezomib plus dexamethasone versus bortezomib monotherapy in patients (pts) with relapsed/refractory multiple myeloma (MM): Interim results from an international electronic observational study
-
Abstract
-
Dimopoulos MA, De Samblanx H, Roussou M, Zervas K, Katodritou E, Sargin D, et al. Efficacy of bortezomib plus dexamethasone versus bortezomib monotherapy in patients (pts) with relapsed/refractory multiple myeloma (MM): interim results from an international electronic observational study. Haematologica. 2011;96 (S78):Abstract P-166.
-
(2011)
Haematologica
, vol.96
, Issue.S78
, pp. 166
-
-
Dimopoulos, M.A.1
De Samblanx, H.2
Roussou, M.3
Zervas, K.4
Katodritou, E.5
Sargin, D.6
-
36
-
-
80053502261
-
-
Yuan ZG, Jin J, Huang XJ, Li Y, Chen WM, Liu ZG, et al. Different dose combinations of bortezomib and dexamethasone in the treatment of relapsed or refractory myeloma: an open-label, observational, multicenter study in China Chin Med J (Engl). 2011;124(19):2969-74.
-
(2011)
Different dose combinations of Bortezomib and Dexamethasone in the treatment of relapsed or refractory myeloma:An open-label, observational, multicenter study in China Chin Med J (Engl)
, vol.124
, Issue.19
, pp. 2969-2974
-
-
Yuan, Z.G.1
Jin, J.2
Huang, X.J.3
Li, Y.4
Chen, W.M.5
Liu, Z.G.6
-
37
-
-
34347365315
-
Daily practice use of Bortezomib in relapsed/refractory multiple myeloma. Safety/efficacy results of a compassionate use program in Switzerland
-
Freimann H, Calderoni A, Cornu P, Olie R. Daily practice use of Bortezomib in relapsed/refractory multiple myeloma. Safety/efficacy results of a compassionate use program in Switzerland. Swiss Med Wkly. 2007;137(21-22):317-22.
-
(2007)
Swiss Med Wkly
, vol.137
, Issue.21-22
, pp. 317-322
-
-
Freimann, H.1
Calderoni, A.2
Cornu, P.3
Olie, R.4
-
38
-
-
84884703399
-
Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): A multicentre, randomised, double-blind study
-
Dimopoulos M, Siegel DS, Lonial S, Qi J, Hajek R, Facon T, et al. Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study. Lancet Oncol. 2013; 14(11):1129-40.
-
(2013)
Lancet Oncol
, vol.14
, Issue.11
, pp. 1129-1140
-
-
Dimopoulos, M.1
Siegel, D.S.2
Lonial, S.3
Qi, J.4
Hajek, R.5
Facon, T.6
-
39
-
-
0035300479
-
The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells
-
Hideshima T, Richardson P, Chauhan D, Palombella VJ, Elliott PJ, Adams J, et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res. 2001;61(7):3071-6.
-
(2001)
Cancer Res
, vol.61
, Issue.7
, pp. 3071-3076
-
-
Hideshima, T.1
Richardson, P.2
Chauhan, D.3
Palombella, V.J.4
Elliott, P.J.5
Adams, J.6
-
40
-
-
35348898377
-
Phase II PETHEMA trial of alternating bortezomib and dexamethasone as induction regimen before autologous stem-cell transplantation in younger patients with multiple myeloma: Efficacy and clinical implications of tumor response kinetics
-
Rosinol L, Oriol A, Mateos MV, Sureda A, Garcia-Sanchez P, Gutierrez N, et al. Phase II PETHEMA trial of alternating bortezomib and dexamethasone as induction regimen before autologous stem-cell transplantation in younger patients with multiple myeloma: efficacy and clinical implications of tumor response kinetics. J Clin Oncol. 2007;25(28):4452-8.
-
(2007)
J Clin Oncol
, vol.25
, Issue.28
, pp. 4452-4458
-
-
Rosinol, L.1
Oriol, A.2
Mateos, M.V.3
Sureda, A.4
Garcia-Sanchez, P.5
Gutierrez, N.6
-
41
-
-
84920165636
-
-
® (bortezomib). Summary of product characteristics (up-dated February 2014). Available from
-
® (bortezomib). Summary of product characteristics (up-dated February 2014). Available from: http://www.ema.europa.eu/ema/index.jsp ?curl=pages/medicines/human/medicines/ 000539/human_med_001130.jsp&mi d=WC0b01ac058001d124.
-
-
-
-
42
-
-
84920158156
-
-
National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Multiple Myeloma. Latest version published online is now V2. 2015. Available from
-
National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Multiple Myeloma. Latest version published online is now V2. 2015. Available from: http://www.nccn.org/professionals/ physician_gls/pdf/myeloma.pdf
-
-
-
-
43
-
-
79952720734
-
Treatment options for relapsed and refractory multiple myeloma
-
Lonial S, Mitsiades CS, Richardson PG. Treatment options for relapsed and refractory multiple myeloma. Clin Cancer Res. 2011;17(6):1264-77.
-
(2011)
Clin Cancer Res
, vol.17
, Issue.6
, pp. 1264-1277
-
-
Lonial, S.1
Mitsiades, C.S.2
Richardson, P.G.3
|